Swiss multinational healthcare firm Roche has introduced three new next-generation sequencing (NGS) Avenio tumor tissue analysis kits for use in oncology research.
The kits, including Avenio tumor tissue targeted kit, expanded kit and surveillance kit, can detect all four mutation classes in solid tumors and complement the firm’s NGS ctDNA kits for oncology research.
Avenio research-use-only (RUO) portfolio of ready-to-use kits includes reagents and software required for labs to determine the genomic characteristics of solid tumors through a single DNA workflow.
Avenio kits use Roche’s enhanced hybrid capture target enrichment techniques to analyze all four mutation classes in a single DNA workflow, including single nucleotide variants (SNVs), insertions or deletions (indels), fusions and copy number variants (CNVs).
Similar to the Avenio ctDNA analysis kits, the Avenio tumor tissue analysis kits are also in line with National Comprehensive Cancer Network (NCCN) guidelines to support oncology research.
Researchers can apply Avenio portfolio of NGS oncology assays to profile the genomic complexities of various solid tumour types by using formalin-fixed paraffin-embedded (FFPE) tissue or plasma to gather detailed results from either workflow within five days.
According to the company, the Avenio tumor tissue analysis kits are for research use only and cannot be used in diagnostic procedures.
Avenio tumor tissue analysis kit is a 17-gene genomic profiling assay, which will help identify guideline-related biomarkers.
Avenio tumor tissue expanded kit is a 77-gene comprehensive genomic profiling assay with both guideline-related and emerging biomarkers to profile well-characterized genetic mutations, as well as those identified in clinical studies.
Avenio tumor tissue Surveillance kit includes 197 genes and is developed for baselining variants in longitudinal tumour burden monitoring applications.
Each kit is provided with reagents required for DNA extraction and quality control (QC), library preparation and target enrichment.
Roche Diagnostics CEO Michael Heuer said: “With the launch of these innovative assays we are pleased to further empower researchers around the world to continue to advance personalized oncology.
“These three ready-to-use Avenio Tumor Tissue Analysis Kits enable researchers by providing relevant panel content that cover all four mutation classes to support the wide variety of cases that require genomic profiling, and complement the previously launched Avenio ctDNA assays for liquid biopsy.”